Target intelligence / Profile preview

Ophthalmic anterior segment tissue (None)

Target
None
01

Overview

Ophthalmic anterior segment tissue is an anatomical designation encompassing the cornea, iris, ciliary body, and lens, which lie at the front of the eye ahead of the vitreous body. These tissues are essential for ocular function: they facilitate light refraction and focusing (cornea, lens), adjustment of depth of focus (ciliary body, lens), regulation of light entry (iris), and maintain intraocular homeostasis via aqueous humor production and drainage (ciliary body, corneal endothelium). Many common eye diseases—including glaucoma, cataract, and corneal infections—involve anterior segment tissues, and many ophthalmic drugs are designed to act upon these tissues, but "ophthalmic anterior segment tissues" itself is not a molecular therapeutic target.

Other names
Anterior segmentanterior eye segmentanterior segment of eyeballanterior cavity of the eye
02

Mechanism of action

Reduction of aqueous humor production (beta blockers, carbonic anhydrase inhibitors); Increase of aqueous humor outflow (prostaglandin analogs); Anti-inflammatory/immunosuppressive effects (corticosteroids); Anti-infective action (antibiotics); Modulation of iris/pupil tone (muscarinic agonists/antagonists)

03

Biological functions

Light refraction (cornea, lens)Aqueous humor production and drainage (ciliary body)Regulation of light entry (iris)Accommodation/focus (ciliary body, lens)
04

Disease associations

Glaucoma (intraocular pressure regulation)Cataract (lens opacification)Corneal diseases (infection, injury)Uveitis (inflammation of iris/ciliary body)Toxic anterior segment syndromeOther (various anterior segment pathologies)
05

Safety considerations

Risk of intraocular infection/inflammationRisk of elevated intraocular pressure (glaucoma)Complications in drug delivery (barriers posed by cornea and blood-ocular barriers)Toxic anterior segment syndrome (post-surgical toxic reaction)Adverse effects on corneal integrity (from drugs or preservatives)
06

Interacting drugs

Anti-glaucoma drugs (e.g., prostaglandin analogs, beta blockers—affect aqueous humor dynamics)

3 more in the full profile.

07

Biomarkers

Intraocular pressure (for glaucoma)Anterior chamber depth (for angle-closure risk)Corneal thickness (for various ocular diseases)Anterior segment imaging parameters

Beyond the preview

Go deeper on Ophthalmic anterior segment tissue (None).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ophthalmic anterior segment tissue (None).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call